Strategic Assessment: MDTI TRUSTEES LIMITED

1. Executive Summary

MDTI Trustees Limited operates as a dormant trustee entity within what appears to be a broader trust and corporate structure, holding nominal assets of £1 since incorporation in 2006. Despite its dormant status and the legal declaration that the entity has never traded, the associated website (mdti.co.uk) describes an active medical device supply business serving the NHS—a critical strategic disconnect that suggests the trading operations are conducted through a separate operating company within the same group. The entity's primary strategic function is structural: serving as a trustee vehicle for Mr Martin Levermore's trust arrangements rather than as an operating business.

2. Strategic Assets

Trust Structure Control: The PSC register reveals a sophisticated control architecture. Mr Levermore exercises control through multiple mechanisms—owning 75%+ of shares as a firm member, holding 75%+ voting rights (both directly and as trustee), and possessing rights to appoint/remove directors. This consolidated control through a trust structure provides significant governance flexibility and potential asset protection advantages.

Longevity and Stability: Nearly two decades of continuous registration (since 2006) with consistent dormant filings demonstrates administrative discipline and regulatory compliance. The entity has maintained its status without dissolution risk, suggesting it serves an enduring structural purpose within the Levermore business ecosystem.

NHS Market Positioning (Indirect): The website content positions the associated brand within the NHS innovation supply chain—specifically in niche medical devices (vaginal dilators for vaginismus and lichen sclerosus, post-surgical knee exercisers, and nose clips). These are specialized products serving underserved clinical needs, typically facing less direct competition than mainstream medical devices.

Regulatory Simplicity: As a dormant company filing under section 480 of the Companies Act 2006, the entity carries minimal compliance burden and zero operational risk exposure.

3. Growth Opportunities

Trust Structure Optimization: The current £1 capitalization represents the absolute minimum. If the trust structure is intended to hold growing asset value or facilitate succession planning, there may be opportunities to capitalize the entity more meaningfully to reflect its true structural importance within the group.

Brand and Digital Asset Consolidation: The mdti.co.uk domain currently describes active medical device operations that are legally dissociated from this entity. Clarifying the relationship between the trustee company, the trading entity, and the brand could unlock better governance transparency and potentially enhance the overall group's credibility with NHS procurement teams—who increasingly scrutinize corporate structures in supplier due diligence.

NHS Innovation Pipeline Expansion: The underlying medical device business (conducted through the operating entity) operates in therapeutic areas with significant unmet need. Vaginismus and lichen sclerosus products serve patient populations historically underserved by medical device innovation. Expansion into adjacent women's health and post-surgical rehabilitation products could leverage existing NHS relationships and procurement frameworks.

Succession and Estate Planning: Given the trust-based control structure, there is a clear opportunity to formalize succession arrangements that preserve both the trading business's continuity and the trust's asset protection benefits—particularly relevant for a founder-controlled enterprise approaching its twentieth year.

4. Strategic Risks

Structural Opacity and Reputational Risk: The disconnect between the dormant, never-traded legal entity and the active commercial website creates potential credibility concerns. NHS procurement processes increasingly demand transparency in beneficial ownership and corporate structure. If the trustee entity's relationship to the trading operations is unclear, it could create friction in tender processes or regulatory scrutiny.

Single-Person Control Concentration: Mr Levermore holds director, secretary, and PSC roles simultaneously, with 75%+ control through multiple mechanisms. While efficient, this concentration creates significant key-person risk. Any incapacity would leave the trust structure and associated operating companies without clear interim governance.

Nominal Capitalization Vulnerability: Persistent £1 net assets across a decade, while appropriate for a dormant entity, provide zero financial resilience. If the trust structure were ever required to meet unexpected obligations—whether through regulatory changes, litigation, or creditor claims against associated entities—the absence of any financial buffer could compromise the structure's integrity.

Market Risk to Underlying Business: The trading entity's reliance on NHS procurement creates concentration risk. NHS budget pressures, policy shifts toward domestic manufacturing, or changes to innovation procurement frameworks could materially impact the operating business whose interests this trustee entity presumably serves.

Compliance Drift: The dual officer roles (Director and Secretary held by the same individual) and the entity's classification as both "Financial Management" (SIC 70221) and a dormant company with an active medical device website suggest potential misalignment between regulatory categorization and actual group function. This could trigger inquiry from Companies House or create complications in any future corporate restructuring.